Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

216 results

Filters applied: . Clear all
Page 1
Tailored anticoagulant treatment after a first venous thromboembolism: protocol of the Leiden Thrombosis Recurrence Risk Prevention (L-TRRiP) study - cohort-based randomised controlled trial.
Burggraaf-van Delft JLI, van Rein N, Bemelmans RHH, van den Berg JK, Bruggeman CY, Cloos-van Balen M, Coppens M, Eefting M, Ende-Verhaar Y, van Es N, van Guldener C, de Jong WK, Kleijwegt F, Koster T, Kroon C, Kuipers S, Leentjens J, Luijten D, Mairuhu ATA, Meijer K, van de Ree MA, Roos R, Schrover I, Swart-Heikens J, van der Velden AWG, van den Akker-van Marle EM, le Cessie S, Geersing GJ, Middeldorp S, Huisman MV, Klok FA, Cannegieter SC; L-TRRiP investigators. Burggraaf-van Delft JLI, et al. BMJ Open. 2024 Mar 23;14(3):e078676. doi: 10.1136/bmjopen-2023-078676. BMJ Open. 2024. PMID: 38521524 Free PMC article.
The aim of the Leiden Thrombosis Recurrence Risk Prevention (L-TRRiP) study is to evaluate the outcomes of tailored duration of long-term anticoagulant treatment based on individualised assessment of rVTE and major bleeding risks. ...
The aim of the Leiden Thrombosis Recurrence Risk Prevention (L-TRRiP) study is to evaluate the outcomes of tailored duration of long-term …
Acute Coronary Syndrome Subphenotypes Based on Repeated Biomarker Measurements in Relation to Long-Term Mortality Risk.
de Bakker M, Scholte NTB, Oemrawsingh RM, Umans VA, Kietselaer B, Schotborgh C, Ronner E, Lenderink T, Aksoy I, van der Harst P, Asselbergs FW, Maas A, Oude Ophuis AJ, Krenning B, de Winter RJ, The SHK, Wardeh AJ, Hermans W, Cramer GE, van Schaik RH, de Rijke YB, Akkerhuis KM, Kardys I, Boersma E; BIOMArCS Investigators †. de Bakker M, et al. Among authors: boersma e. J Am Heart Assoc. 2024 Jan 16;13(2):e031646. doi: 10.1161/JAHA.123.031646. Epub 2024 Jan 12. J Am Heart Assoc. 2024. PMID: 38214281 Free PMC article.
The temporal biomarker patterns of patients in cluster 3 were similar to those with a repeat ACS during the first year. Clusters 1 and 2 had a similar and favorable long-term mortality risk. Cluster 3 had the highest mortality risk. The adjusted survival time ratio was 0.6 …
The temporal biomarker patterns of patients in cluster 3 were similar to those with a repeat ACS during the first year. Clusters 1 and 2 had …
Machine learning-based biomarker profile derived from 4210 serially measured proteins predicts clinical outcome of patients with heart failure.
de Bakker M, Petersen TB, Rueten-Budde AJ, Akkerhuis KM, Umans VA, Brugts JJ, Germans T, Reinders MJT, Katsikis PD, van der Spek PJ, Ostroff R, She R, Lanfear D, Asselbergs FW, Boersma E, Rizopoulos D, Kardys I. de Bakker M, et al. Among authors: boersma e. Eur Heart J Digit Health. 2023 Oct 4;4(6):444-454. doi: 10.1093/ehjdh/ztad056. eCollection 2023 Dec. Eur Heart J Digit Health. 2023. PMID: 38045440 Free PMC article.
CLINICAL TRIAL REGISTRATION: https://clinicaltrials.gov/ct2/show/NCT01851538?term=nCT01851538&draw=2&rank=1 24....
CLINICAL TRIAL REGISTRATION: https://clinicaltrials.gov/ct2/show/NCT01851538?term=nCT01851538&draw=2&rank=1 24....
Cardiac rehabilitation for patients with obesity: lessons learned from the OPTICARE XL trial.
den Uijl I, Sunamura M, Brouwers RMW, Stam HJ, Boersma E, van den Berg-Emons RJG, Ter Hoeve N. den Uijl I, et al. Among authors: boersma e. Neth Heart J. 2024 Jan;32(1):14-22. doi: 10.1007/s12471-023-01832-w. Epub 2023 Nov 20. Neth Heart J. 2024. PMID: 37982980 Free PMC article. Review.
However, the OPTICARE XL CR program did not show long-term added value compared with standard CR on health-related quality of life, psychosocial well-being, body weight, physical activity and physical fitness, nor on costs. The current article offers an overview of the bac …
However, the OPTICARE XL CR program did not show long-term added value compared with standard CR on health-related quality of life, p …
Metabolic disorders mediate the relation of miscarriage with cardiovascular diseases.
Zhu F, Noordermeer D, Aribas E, Bos M, Boersma E, Kavousi M. Zhu F, et al. Among authors: boersma e. Eur J Prev Cardiol. 2024 Feb 15;31(3):330-336. doi: 10.1093/eurjpc/zwad347. Eur J Prev Cardiol. 2024. PMID: 37939791
AIMS: The extent to which the contribution of pregnancy loss to cardiovascular diseases (CVDs) can be explained by metabolic disorders is poorly elucidated but holds insights for reducing long-term cardiovascular risk. The aim of this study is to investigate the mediating …
AIMS: The extent to which the contribution of pregnancy loss to cardiovascular diseases (CVDs) can be explained by metabolic disorders is po …
Long-term glucocorticoids in relation to the metabolic syndrome and cardiovascular disease: A systematic review and meta-analysis.
Kuckuck S, Lengton R, Boon MR, Boersma E, Penninx BWJH, Kavousi M, van Rossum EFC. Kuckuck S, et al. Among authors: boersma e. J Intern Med. 2024 Jan;295(1):2-19. doi: 10.1111/joim.13739. Epub 2023 Nov 5. J Intern Med. 2024. PMID: 37926862 Review.
The striking link of Cushing's syndrome with the metabolic syndrome (MetS) and cardiovascular disease (CVD) suggests that long-term exposure to extremely high cortisol levels catalyzes cardiometabolic deterioration. ...Results regarding the associations of HairF and HairE …
The striking link of Cushing's syndrome with the metabolic syndrome (MetS) and cardiovascular disease (CVD) suggests that long-term e …
Effects of a Dedicated Cardiac Rehabilitation Program for Patients With Obesity on Body Weight, Physical Activity, Sedentary Behavior, and Physical Fitness: The OPTICARE XL Randomized Controlled Trial.
den Uijl I, van den Berg-Emons RJG, Sunamura M, Lenzen MJ, Stam HJ, Boersma E, Tenbült-van Limpt NCCW, Kemps HMC, Geleijnse ML, Ter Hoeve N. den Uijl I, et al. Among authors: boersma e. Phys Ther. 2023 Sep 1;103(9):pzad055. doi: 10.1093/ptj/pzad055. Phys Ther. 2023. PMID: 37265452 Free PMC article. Clinical Trial.
CONCLUSION: Patients allocated to OPTICARE XL CR lost significantly more body weight and showed promising results with respect to physical activity 3 months after the start of CR; however, these short-term results were not expanded or sustained in the longer term. I …
CONCLUSION: Patients allocated to OPTICARE XL CR lost significantly more body weight and showed promising results with respect to physical a …
Remote haemodynamic monitoring of pulmonary artery pressures in patients with chronic heart failure (MONITOR-HF): a randomised clinical trial.
Brugts JJ, Radhoe SP, Clephas PRD, Aydin D, van Gent MWF, Szymanski MK, Rienstra M, van den Heuvel MH, da Fonseca CA, Linssen GCM, Borleffs CJW, Boersma E, Asselbergs FW, Mosterd A, Brunner-La Rocca HP, de Boer RA; MONITOR-HF investigators. Brugts JJ, et al. Among authors: boersma e. Lancet. 2023 Jun 24;401(10394):2113-2123. doi: 10.1016/S0140-6736(23)00923-6. Epub 2023 May 20. Lancet. 2023. PMID: 37220768 Clinical Trial.
There is a clear need for randomised trial data from patients treated with contemporary guideline-directed-medical-therapy with long-term follow-up in a different health-care system. METHODS: MONITOR-HF was an open-label, randomised trial, done in 25 centres in the Netherl …
There is a clear need for randomised trial data from patients treated with contemporary guideline-directed-medical-therapy with long-term …
LDL cholesterol targets rarely achieved in familial hypercholesterolemia patients: A sex and gender-specific analysis.
Schreuder MM, Hamkour S, Siegers KE, Holven KB, Johansen AK, van de Ree MA, Imholz B, Boersma E, Louters L, Bogsrud MP, Retterstøl K, Visseren FLJ, Roeters van Lennep JE, Koopal C. Schreuder MM, et al. Among authors: boersma e. Atherosclerosis. 2023 Nov;384:117117. doi: 10.1016/j.atherosclerosis.2023.03.022. Epub 2023 Apr 13. Atherosclerosis. 2023. PMID: 37080805 Free article.
Extra efforts have to be made to provide FH patients with reliable information on the safety of statins and their long-term effects on CVD risk reduction. If statin treatment is insufficient, alternative lipid lowering therapies such as ezetimibe or PCSK9-inhibitors should …
Extra efforts have to be made to provide FH patients with reliable information on the safety of statins and their long-term effects o …
Effects of enzyme replacement therapy on cardiac function in classic infantile Pompe disease.
Scheffers LE, Kok R, van den Berg LE, van den Hout JMP, Boersma E, van Capelle CI, Helbing WA, van der Ploeg AT, Koopman LP. Scheffers LE, et al. Among authors: boersma e. Int J Cardiol. 2023 Jun 1;380:65-71. doi: 10.1016/j.ijcard.2023.03.010. Epub 2023 Mar 8. Int J Cardiol. 2023. PMID: 36893858 Free article.
Separate linear mixed effect models were used to asses temporal changes within the first year and the long-term follow-up period. Echocardiograms of 103 healthy children served as controls. ...
Separate linear mixed effect models were used to asses temporal changes within the first year and the long-term follow-up period. Ech …
216 results